BMRN Historical PE Ratio Notes

— BioMarin Pharmaceutical Inc. (BMRN) is a biotechnology company specializing in the development & commercialization of therapies for rare genetic diseases, particularly in areas such as enzyme replacement therapies & gene therapies. The company's product portfolio targets conditions with high unmet medical need, including disorders like phenylketonuria and various mucopolysaccharidoses. Due to the niche markets it serves, BioMarin's revenues can fluctuate based on the approval & uptake of new treatments, clinical trial outcomes, and regulatory developments. When analyzing BMRN's historical price-to-earnings (PE) ratio, investors should note that biotech firms like BioMarin often post periods of negative or volatile earnings, especially during research & development-intensive phases, which can cause the reported PE ratios to spike, become irregular, or be temporarily undefined (when earnings are negative). Even during profitable periods, the stock market may assign high PE multiples in anticipation of future growth from breakthrough therapies, rather than current profitability. Therefore, when you review historical PE ratio charts & tables for BMRN, keep in mind the underlying business model's dependence on a few high-value products, long R&D cycles, & the frequent reinvestment of cash flows, all of which contribute to sometimes elevated or unstable PE ratios compared to companies with steady earnings streams.

On this page we presented the BMRN Historical PE Ratio information for Biomarin Pharmaceutical' stock. The average BMRN historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 76.0. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average BMRN historical PE based on this TTM earnings result method is 76.7. Note: any PE calculations resulting in a value exceeding 500 were discarded as not meaningful. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this BMRN historical PE result, against the recent PE: when this page was posted on 3/13/2026, the most recent closing price for BMRN had been 58.51, and the most recent quarterly earnings result, annualized, was 1.84. Meanwhile, the most recent TTM earnings summed to 3.15. From these numbers, we calculate the recent BMRN PE on 3/13/2026 based on annualized quarterly EPS was 31.8. Based on BMRN's history, that recent PE is low relative to the historical average, with the recent PE 58.2% lower than the historical average PE across our data set for Biomarin Pharmaceutical. Looking at the recent BMRN PE on 3/13/2026 based on TTM EPS, we calculate the ratio at 18.6. Based on BMRN's history, that recent PE is low relative to the historical average, with the recent PE 75.7% lower than the average PE across our Biomarin Pharmaceutical data set with TTM EPS used in the calculation at each period.

Another interesting BMRN historical PE Ratio calculation we look at is to take the median earnings per share of the last four quarters for BMRN, and then annualize the resulting value... with that annualized number then being used in the PE calculation. To walk through this math for BMRN, we start with the past four EPS numbers and we first sort them from lowest to highest: 0.12, 0.46, 1.13, and 1.44. We then toss out the highest and lowest result, and then take the average of those two middle numbers — 0.46 and 1.13 — which gives us the median of 0.79. Basically the way to think about this 0.79 number is this: for the trailing four earnings reports, 0.79 marks the "middle ground" number where BMRN has reported a value higher than 0.79 half the time, and has reported a value lower than 0.79 half the time. Annualizing that median value then gets us to 3.16/share, which we use as the denominator in our next PE calculation. With 58.51 as the numerator (as of 3/13/2026), the calculation is then 58.51 / 3.16 = 18.5 as the BMRN PE ratio as of 3/13/2026, based on that annualized median value we calculated.

For self directed investors doing their due diligence on BMRN or any other given stock, valuation analysis for BMRN can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Biomarin Pharmaceutical PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for BMRN. Thanks for visiting, and the next time you need to research BMRN Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.